ijms-logo

Journal Browser

Journal Browser

Molecular Pharmacology and Interventions in Cardiovascular Disease: 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 394

Special Issue Editor


E-Mail Website
Guest Editor
Department of Physiology, Medical University of Gdansk, 80-210 Gdansk, Poland
Interests: heart metabolism; purine metabolism; ischemic heart disease; cardioplegia; myocardial ischemia and infarction; cardiac energetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The prevalence of cardiovascular diseases, which are complex and multifunctional, rises as the mean age of the population increases. The size of the myocardial infarction remains a crucial therapeutic target, because it correlates with heart failure and mortality. Efforts are being directed towards the development of novel drugs via the physiochemical modification of drug molecules and the design and synthesis of new drugs, with an emphasis on drug delivery, controlled drug release, and the targeting of drugs to the site of action in order to enhance the therapeutic effect.

While numerous pre-clinical studies have revealed that certain pharmacologic agents and therapeutic maneuvers reduce the myocardial infarction size more significantly than reperfusion alone, very few of these therapies have translated into successful clinical trials or standard clinical application. The optimization of pharmacologic agents is critical to the development of diagnostic, treatment, and preventive strategies in the cardiology field. It is essential to promote the endogenous regeneration of the heart in order to improve the prognosis of patients with cardiac injury and to find effective therapeutic strategies for it.

This Special Issue focuses on the role of cardiovascular pharmacology and interventions in cardiac injury, aiming to elucidate pharmacologic strategies that may be employed to promote heart repair after cardiac injury.

Dr. Magdalena Zabielska-Kaczorowska
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular pharmacology
  • cardiovascular interventions
  • cardioprotection
  • myocardial ischemia and infarction
  • heart failure

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 5657 KiB  
Article
SUL-150 Limits Vascular Remodeling and Ventricular Failure in Pulmonary Arterial Hypertension
by Lysanne M. Jorna, Dalibor Nakládal, Johannes N. van Heuveln, Diederik E. van der Feen, Quint A. J. Hagdorn, Guido P. L. Bossers, Annemieke van Oosten, Michel Weij, Ludmila Tkáčiková, Soňa Tkáčiková, Robert H. Henning, Martin C. Harmsen, Rolf M. F. Berger and Guido Krenning
Int. J. Mol. Sci. 2025, 26(15), 7181; https://doi.org/10.3390/ijms26157181 - 25 Jul 2025
Viewed by 281
Abstract
Pulmonary arterial hypertension (PAH) is a rare, progressive, and incurable disease characterized by an elevated pulmonary blood pressure, extensive remodeling of the pulmonary vasculature, increased pulmonary vascular resistance, and culminating in right ventricular failure. Mitochondrial dysfunction has a major role in the pathogenesis [...] Read more.
Pulmonary arterial hypertension (PAH) is a rare, progressive, and incurable disease characterized by an elevated pulmonary blood pressure, extensive remodeling of the pulmonary vasculature, increased pulmonary vascular resistance, and culminating in right ventricular failure. Mitochondrial dysfunction has a major role in the pathogenesis of PAH and secondary right ventricular failure, and its targeting may offer therapeutic benefit. In this study, we provide proof-of-concept for the use of the mitochondrially active drug SUL-150 to treat PAH. PAH was induced in rats by monocrotaline, followed by the placement of an aortocaval shunt one week later. The mitoprotective compound SUL-150 (~6 mg·kg−1·day−1) or vehicle was administered intraperitoneally via osmotic minipump for 28 days, implanted at the time of aortocaval shunt placement. Vehicle-treated PAH rats had dyspnea and showed pulmonary artery remodeling with increased responsiveness to phenylephrine, in addition to remodeling of the intrapulmonary arterioles. SUL-150 administration mitigated the dyspnea and the remodeling responses. Vehicle-treated PAH rats developed right ventricular hypertrophy, fibrosis, and failure. SUL-150 administration precluded cardiomyocyte hypertrophy and inhibited ventricular fibrogenesis. Right ventricular failure in vehicle-treated PAH rats induced mitochondrial loss and dysfunction associated with a decrease in mitophagy. SUL-150 was unable to prevent the mitochondrial loss but improved mitochondrial health in the right ventricle, which culminated in the preservation of right ventricular function. We conclude that SUL-150 improves PAH-associated morbidity by the amelioration of pulmonary vascular remodeling and right ventricular failure and may be considered a promising therapeutic candidate to slow disease progression in pulmonary arterial hypertension and secondary right ventricular failure. Full article
Show Figures

Figure 1

Back to TopTop